Filtered By:
Condition: Cholesterol
Therapy: Statin Therapy
Countries: USA Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Researcher Studies Statins for Stroke Therapy
Stacy Pigott A $2.8 million grant may help develop an improved therapeutic treatment for acute ischemic stroke patients to let them recover faster with fewer long-term complications. The protocol hinges on effectively delivering statins to the brain, where their neuroprotective properties can help save tissue damaged by stroke. Aug. 7, 2020 University of Arizona Health Sciencesnhg-PATRICK-RONALDSON_DSC6492-web.jpg Patrick Ronaldson (right), associate professor in the College of Medicine – Tucson's Department of Pharmacology, and doctoral students Erica Williams and Robert Betterton discuss their latest researc...
Source: The University of Arizona: Health - August 6, 2020 Category: Universities & Medical Training Authors: mittank Source Type: research

Stenosis Length and Degree Interact With the Risk of Cerebrovascular Events Related to Internal Carotid Artery Stenosis
Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of sICAS<70% to be longer than that of sICAS≥70%. Moreover, the ultrasound-measured length of sICAS<90% was significantly longer than that of sICAS 90%. Among patients with sICAS≥70%, the degree and length of stenosis were inversely correlated. Larger studies are needed before a clinical implication can be drawn from these results. Introduction Internal carotid artery stenosis (ICAS) causes around one-fifth of ischemic cerebrovascular stroke and has the highest risk of early stroke recurrence...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Asymptomatic Carotid Stenosis Is Associated With Circadian and Other Variability in Embolus Detection
Conclusions: Embolism associated with asymptomatic carotid stenosis shows circadian variation with highest rates 4–6 h before midday. This corresponds with peak circadian incidence of stroke and other vascular complications. These and ASED Study results show that monitoring frequency, duration, and time of day are important in ES detection. Introduction Transcranial Doppler (TCD) detected microembolism in the ipsilateral middle cerebral artery (MCA) may help stratify the risk of stroke and other arterial disease complications in persons with advanced (≥60%) asymptomatic carotid stenosis. If so, this t...
Source: Frontiers in Neurology - April 15, 2019 Category: Neurology Source Type: research

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research

Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT)
Conclusion and relevance High-dose oral multivitamin and multimineral supplementation seem to decrease combined cardiac events in a stable, post-MI population not taking statin therapy at baseline. These unexpected findings are being retested in the ongoing TACT2.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research

HIV-positive adults are under-treated for cardiovascular problems compared to those without HIV
This study provides evidence that U.S. policymakers and professional societies should focus on improving the quality of the cardiovascular care that people who are HIV-positive receive.AUTHORSStudy authors are Dr. Joseph Ladapo, Dr. Adam Richards, Cassandra DeWitt, Nina Harawa, Steven Shoptaw, Dr. William Cunningham and Dr. John Mafi, all of UCLA. Mafi is also associated with Rand Corporation.JOURNALThestudy is published in the Journal of the American Heart Association.FUNDINGGrants from the National Heart, Lung and Blood Institute, National Institute on Minority Health and Health Disparities, and National Institute of Men...
Source: UCLA Newsroom: Health Sciences - November 22, 2017 Category: Universities & Medical Training Source Type: news

Invited commentary
Although carotid endarterectomy and stenting for symptomatic significant carotid artery stenosis are widely accepted for stroke prevention, their use for asymptomatic stenosis is more controversial. With the advances in medical therapy, particularly the use of statins, and with an annual stroke risk of 1% to 2% for asymptomatic disease, justifying these interventions in these patients is more difficult. What is more disturbing is that ∼90% of all carotid endarterectomy and stenting procedures in the United States are performed on asymptomatic patients and that many were felt to be unnecessary, resulting in a cost of>$2 billion annually.
Source: Journal of Vascular Surgery - April 20, 2018 Category: Surgery Authors: Ali F. AbuRahma Tags: From bench to bedside Source Type: research

Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage. Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news

Abstract 243: A Novel Cost Effectiveness Model of Eicosapentaenoic Acid (EPA) for Secondary Prevention in the United States Session Title: Poster Session II
Conclusions: This novel model suggests that combining EPA with statin therapy for secondary prevention of cardiovascular disease in the United States may be cost-saving and appears to be a more compelling intervention than statin monotherapy. The framework of this model provides a starting point for development of microsimulation models as more data become available.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Schmier, J. K., Hulme-Lowe, C., Nelson, J. R., Chowdhury, S., Everett, P. B., Philip, S. Tags: Session Title: Poster Session II Source Type: research

Prescription of Statins to Women Poses New Clinical Challenges
In women and men, cardiovascular disease is and will remain the leading avoidable cause of premature death in the United States and is rapidly becoming so worldwide. (1) While many women fear breast cancer more than cardiovascular disease, 1 in 8 will develop and 1 in 25 will die from this disease whereas over 1 in 3 will die from coronary heart disease and 1 in 6 from stroke. (2)
Source: The American Journal of Medicine - April 18, 2018 Category: General Medicine Authors: Madeline Pung, Janet Robishaw, Marc A. Pfeffer, Charles H. Hennekens Tags: Commentary Source Type: research

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Conclusion: The price of alirocumab would have to be reduced considerably to be cost-effective. Because substantial reductions already have occurred, we believe that timely, independent cost-effectiveness analyses can inform clinical and policy discussions of new drugs as they enter the market. Primary Funding Source: University of California, San Francisco, and Institute for Clinical and Economic Review. PMID: 30597485 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 1, 2019 Category: Internal Medicine Authors: Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K Tags: Ann Intern Med Source Type: research

Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
ConclusionsHigher VLDL-C and Apo-B levels, as well as lower HDL-C and Apo-AI levels, are associated with increased risk for ASCVD. These findings support future investigations into pharmacologic targeting of lipoproteins beyond LDL-C, such as triglyceride-rich lipoproteins, to reduce residual risk for ASCVD among individuals with CKD.
Source: American Journal of Kidney Diseases - January 25, 2019 Category: Urology & Nephrology Source Type: research